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Abstract 
Although jaundice rarely complicates polycystic liver disease (PLD), secondary benign or 
malignant causes cannot be excluded. In a 72-year-old female who presented with 
increased abdominal girth, dyspnea, weight loss and jaundice, ultrasound and computed 
tomography confirmed the diagnosis of PLD by demonstrating large liver cysts causing 
extrahepatic bile duct compression. Percutaneous cyst aspiration failed to relief jaundice 
due to distal bile duct cholangiocarcinoma, suspected by magnetic resonance 
cholangiopancreatography (MRCP) and confirmed by endoscopic retrograde 
cholangiopancreatography (ERCP). Coexistence of PLD with distal common bile duct 
cholangiocarcinoma has not been reported so far. 
 
Introduction 
Polycystic liver disease (PLD) is a genetic inherited entity associated with polycystic 
renal disease due to mutations in PKD1 or PKD2 genes [1]. A rarer PRKCSH gene 
mutation exists and is associated with isolated multiple liver cysts [2]. Symptoms are 
unspecific and are caused by increased liver volume and adjacent visceral compression. 
Surgical intervention is needed in cases presenting with massive hepatomegaly, or when 
complications such as cyst rupture, infection, hemorrhage or jaundice occur. Obstructive 
jaundice is a rare finding usually associated with secondary causes rather than external 
cyst compression of the bile ducts [3]. Although there are reports in the literature of cyst- 
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associated jaundice [4, 5] our experience suggests that a thorough workup to exclude 
secondary causes such as gallstones and malignancy is mandatory. 
Case Report 
A 72-year-old Caucasian female presented with increased abdominal girth and jaundice. She 
complained of chronic dull pain, satiety, weight loss, dyspnea and physical disability. The patient had 
had clay-coloured stools and dark urine the last two weeks before admission. 
Physical examination revealed a large non-tender abdominal mass and no signs of chronic liver 
disease such as splenomegaly or ascites. 
Liver function tests were compatible with obstructive jaundice, with total bilirubin 8.07 mg/dl 
(normal range <1 mg/dl), with direct predominance (7.51 mg/dl) and elevation of alkaline phosphatase 
(337 U/l, normal range 50–136U/l) and γ-GT (404 U/l, normal range 15–85 U/l). Ca19-9 value was 224 
U/ml (normal range 0–37 U/ml). 
Ultrasound examination of the abdomen showed multiple liver cysts ranging from 1.2 to 13 cm in 
diameter and dilated intrahepatic biliary ducts. Computed tomography (CT) scan was performed using 
the standard protocol for hepatobiliary disease evaluation (slice thickness 3–5 mm, arterial-portal 
venous and delayed phases after contrast administration). The multicystic nature of the disease was 
documented. The two dominant large liver cysts were located adjacent to the hilum. 
Percutaneous drainage of the hilar cysts was performed to confirm that subsequent fenestration or 
enucleation will resolve jaundice. However the persistence of cholestasis and the mild dilatation of 
intrahepatic bile ducts in the post drainage CT evaluation (fig. 1) indicated the coexistence of a 
secondary cause. The patient underwent magnetic resonance imaging and magnetic resonance 
cholangiopancreatography (MRI-MRCP) that was compatible with the presence of possible 
neoplasmatic infiltration at the distal common bile duct, since duct compression was not marked 
enough to justify intrahepatic biliary dilatation and furthermore the distal segment of the common bile 
duct was not evident (fig. 2). Endoscopic retrograde cholangiopancreatography (ERCP) was performed 
(fig. 3). The abrupt termination of the middle segment of the common bile duct was indicative of 
neoplastic infiltration. Brushing followed and confirmed the diagnosis of cholangiocarcinoma. 
Pylorus-preserving pancreato-duodenectomy with dominant liver cyst enucleation was performed. 
Histopathological examination revealed a biliary adenocarcinoma of the distal common bile duct. The 
postoperative period was uneventful and the patient was discharged on the 9th postoperative day. At 
six-month follow-up the patient is free of recurrence. 
Discussion 
PLD is inherited as an autosomal dominant trait presenting in adulthood. Autosomal 
dominant polycystic disease is genetically heterogeneous, with mutations in two distinct 
genes predisposing to the combination of renal and liver cysts (AD-PKD1 and AD-PKD2) 
[1]. Furthermore, Davila et al. [2] reported a second gene (SEC6) related to PLD. This 
gene encodes a component of the protein translocation machinery in the endoplasmatic 
reticulum. 
The disease is more frequent in women, and hepatic cysts can increase dramatically in 
number and size through the child-bearing years of early and middle adult life. The cysts 
in PLD can also increase in size and number during pregnancy or simultaneously with the 
use of exogenous female steroid hormones [6]. In one study it was shown that the use of 
estrogen in women with autosomal dominant polycystic kidney disease may selectively 
increase the severity of hepatic cystic disease [7]. 
Symptoms are caused by increased liver volume and adjacent visceral compression. 
Usually patients suffer from chronic dull abdominal pain, satiety, weight loss, dyspnea,  
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physical disability and descensus. Liver function tests are usually normal except for mild 
elevation in ALP or γ-GT. Jaundice may rarely exist due to compression of the common 
bile duct by the cysts [8]. In our experience, including this case, obstructive jaundice is 
usually associated with a co-existing underlying pathology such as gallstone disease or 
malignancy. 
In PLD, liver failure or complications of advanced liver disease are rare. Even with 
marked hepatosplenomegaly and portal hypertension, liver function is well preserved. 
Thus jaundice is uncommon and requires further exploration to exclude benign or 
malignant disease. In our case the final diagnosis related to jaundice was a co-existing 
biliary adenocarcinoma. Other authors have reported co-existing choledocholithiasis and 
other complications of PLD causing obstructive jaundice [9]. 
In case of jaundice, standard pre and post contrast MRI sequences are necessary to 
establish the presence of an underlying malignancy that may be suggested by the biliary 
dilatation seen at MRCP. MRCP is also helpful to estimate the intraductal extent of tumor 
infiltration, facilitating surgical planning. ERCP can also help to confirm the cause of 
jaundice, presenting the further advantage of performing brushing or biopsy. The 
presence of the cholangiocarcinoma in the distal common bile duct, as was shown on 
imaging in our case, led the surgical team to perform a successful pylorus-preserving 
pancreatoduodenectomy with dominant liver cysts enucleation, which was considered the 
best therapeutic option for the patient. 
Cholangiocarcinoma is the most common primary malignancy of the bile ducts and 
accounts for 15–50% of obstructing bile duct tumors [10]. Factors that predispose to the 
development of cholangiocarcinoma include ulcerative colitis, primary sclerosing 
cholangitis, choledochal cysts, Caroli disease, polyposis syndromes of the colon and 
Clonorchis sinensis infestation [10]. Cholangiocacinomas are generally classified as 
intrahepatic (peripheral) lesions, hilar lesions, and distal ductal tumors. CT appearance 
depends on their location, morphology and tumor pathology. If no tumor mass is seen, 
diagnosis of hilar cholangiocarcinoma can be made by the presence of high-grade 
intrahepatic bile duct dilatation and the absence of right and left hepatic duct union. If the 
neoplasm is located at a lower level, as in our case, at the point of obstuction the duct will 
terminate abruptly or there may be associated eccentric thickening of bile duct wall [11–
13]. The reason of the nonvisibility of the cholangiocarcinoma on CT images in our 
patient could be attributed to cyst superimposition obscuring the lesion and to the 
infiltrative type of the neoplasm, as was proven on histopathology, characterized by the 
absence of tumor mass. 
MRCP is essential for the accurate estimation of obstruction level and the depiction of 
the characteristic morphologic features of stenosis or obstruction (abrupt termination of 
the bile duct as in our case) [14]. Because of their intrinsic high tissue contrast and 
multiplanar capability, MRI and MRCP are able to detect and preoperatively assess 
patients with cholangiocarcinoma, investigating all involved structures such as bile ducts, 
vessels and hepatic parenchyma. The main reason for surgical/imaging discrepancy is 
represented by the microscopic diffusion along the mucosa and in the perineural space. It 
should also be emphasized that the presence of multiple cystic liver lesions superimposed 
on the biliary ducts, displacing or distorting them, may obscure the presence of a 
cholangiocarcinoma. On the other hand, false-negative results are also encountered with 
ERCP washing or brushing in some patients due to the submucosal tumor growth. 
Intrahepatic cholangiocarcinoma occurs rarely in patients with multiple liver cysts and 
tumor origin from cysts after in situ transformation of the epithelium has been shown in  
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some cases [15–18]. The prognosis of cholangiocarcinoma associated with PLD is very 
poor and distant metastases are common. The possibility of cholangiocarcinoma should 
be considered in any patient with autosomal dominant polycystic kidney disease with 
significant abnormal liver function tests. After extensive review of the literature, it 
appears that coexistence of PLD with distal common bile duct cholangiocarcinoma as in 
our case has not been reported so far. 
Less than 5% of patients with PLD have acute medical complications. These consist of 
cyst hemorrhage, rupture, infection, uterine prolapse due to displacement, obstructive 
jaundice, portal hypertension, transudative and exudative ascites and Budd-Chiari 
syndrome [19, 20]. Surgery is indicated in most cases, as medical treatment has failed to 
show any efficacy. Use of somatostatin to block the secretin-induced secretion by hepatic 
cysts failed to demonstrate any significant effect on hepatic cyst growth size [21]. Cyst 
aspiration with sclerosis, open or laparoscopic cyst fenestration, combined hepatic 
resection and fenestration or liver transplantation are possible treatment options. 
Treatment approaches should be individualized based on the type of PLD. 
Aspiration combined with ethanol instillation to induce sclerosis of the cyst lining 
epithelium can be effective in patients with a few dominant cysts (type I PLD – few large 
cysts >7 cm). However, long-term recurrence presents in 50% of cases [22]. Cyst 
fenestration can be performed in patients with more diffuse PLD (type II PLD – multiple 
medium cysts 5–7 cm in diameter). Morbidity after laparoscopic fenestration ranges 
between 33 and 45%, with high recurrence rate. Patients with small cysts throughout the 
liver have a greater risk of persistence and recurrence of symptoms. 
Combined hepatic resection and fenestration is more effective in reducing the hepatic 
mass and gastric compression. Recurrence rates vary significantly in the literature with 
high postoperative morbidity rates (38–100%) [23]. This procedure offers an additional 
advantage in the case of massive hepatomegaly and severe symptoms of gastric 
compression. Resection addresses the problem of liver mass, but poses a significant risk of 
biliary ductal injury, vascular compromise, and liver insufficiency because cysts markedly 
distort the intrahepatic anatomy [24]. Postoperative morbidity is related to the presence 
of temporary ascites, pleural effusion and biliary leakage. In particular, ascites has been 
troublesome due to continued cyst secretion from residual fenestrated cysts, disruption of 
intrahepatic lymphatics and partial venous outflow obstruction. Candidates for combined 
resection/fenestration should have at least two adjacent liver segments not involved by 
cysts and normal liver function. These patients should be also managed by experienced 
hepatobiliary surgeons at institutions with advanced intensive care and interventional 
radiological and gastroenterology support. 
Liver transplantation has been performed in rare cases when the above-mentioned 
interventions were not an option. In patients who harbour diffuse PLD, orthotopic liver 
transplantation is effective, but inherently assumes the risks of long-term 
immunosuppression and rejection. Orthotopic liver transplantation is indicated for 
patients with progressive PLD after resection/fenestration, patients with concurrent liver 
dysfunction and renal failure, and patients with diffuse PLD without segmental sparing 
[25].  
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Conclusion 
Isolated PLD is a rare entity. Jaundice presents infrequently in this group of patients, 
unless a secondary cause exists. In such situations a thorough diagnostic workup is 
mandatory to exclude the coincidence of benign or malignant disease. 
 
 
 
 
 
Fig. 1. Non-contrast CT image after percutaneous drainage of the two larger hepatic cysts. Mild 
intrahepatic biliary dilatation is evident (arrows). 
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Fig. 2. MRCP image (T2-weighted sequence): multiple hepatic cysts are shown (arrows) while the 
common bile duct seems mildly compressed (arrowheads) between the two larger cysts. The distal 
segment of the common bile duct is not evident. 
 
 
 
Fig. 3. ERCP image during the procedure of stent placement. Prominent intra- and extrahepatic bile 
duct dilatation with abrupt termination of the middle segment of the common bile duct (arrow) is 
shown consistent with neoplastic disease. 
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